Novartis AG Says Experimental Drug Helps Chronic Migraine Sufferers
About 40 percent of chronic migraine sufferers taking an experimental drug developed by Novartis and Amgen saw the number of days they suffered a migraine cut by at least half, beating the placebo in the trial.
The latest analysis from the mid-phase study amounted to a "statistically significant reduction in monthly migraine days", Novartis said about the experimental AMG 334 compound.
Novartis has struck pacts with its U.S.-based rival Amgen to develop migraine and Alzheimer's treatments as it seeks to bolster its neuroscience portfolio.
The latest analysis from the mid-phase study amounted to a "statistically significant reduction in monthly migraine days", Novartis said about the experimental AMG 334 compound.
Novartis has struck pacts with its U.S.-based rival Amgen to develop migraine and Alzheimer's treatments as it seeks to bolster its neuroscience portfolio.